Squarepoint
IMNM icon

Squarepoint’s Immunome IMNM Stock Holding History

Squarepoint’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-67,778
Closed -$1.48M – 4685
2026
Q1 		$1.48M Buy
67,778
+38,445
+131% +$856K ﹤0.01% 2432
2025
Q4 		$630K Buy
+29,333
New +$515K ﹤0.01% 3015
2025
Q1 		– Sell
-17,914
Closed -$190K – 4975
2024
Q4 		$190K Sell
17,914
-13,772
-43% -$166K ﹤0.01% 4489
2024
Q3 		$463K Sell
31,686
-42,243
-57% -$600K ﹤0.01% 3152
2024
Q2 		$895K Sell
73,929
-45,843
-38% -$717K ﹤0.01% 2641
2024
Q1 		$2.96M Buy
+119,772
New +$2.43M 0.01% 1836

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Squarepoint's IMNM Position: Q2 2026 in Review

Squarepoint sold out of Immunome (IMNM) in Q2 2026, closing a stake of 67,778 shares — an estimated $1.48M sold.

Squarepoint first reported a position in IMNM in Q1 2024 and held it in 6 quarters. The position peaked at $2.96M in Q1 2024. 203 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Squarepoint reported no remaining Immunome position as of Q2 2026 after selling out during the quarter.
  • Squarepoint sold 67,778 Immunome shares in Q2 2026, an estimated $1.48M.
  • Squarepoint first reported a position in Immunome in Q1 2024 and held it in 6 quarters.
  • Squarepoint's Immunome position peaked at $2.96M in Q1 2024.
  • 203 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.